Last update 01 Jun 2025

Lopinavir/Ritonavir

Overview

Basic Info

Drug Type
Small molecule drug
Synonyms
ABT-378/Ritonavir, DARE-HPV, Lopinavir and Ritonavir
+ [10]
Target
Action
inhibitors
Mechanism
HIV-1 pol inhibitors(Human immunodeficiency virus type 1 Pol protein inhibitors)
Originator Organization
Inactive Organization
License Organization-
Drug Highest PhaseApproved
First Approval Date
United States (15 Sep 2000),
RegulationAccelerated Approval (United States)
Login to view timeline

Structure/Sequence

Molecular FormulaC37H48N4O5
InChIKeyKJHKTHWMRKYKJE-SUGCFTRWSA-N
CAS Registry192725-17-0
View All Structures (2)

External Link

KEGGWikiATCDrug Bank
-Lopinavir/Ritonavir-

R&D Status

Approved
10 top approved records.
Login
to view more data
IndicationCountry/LocationOrganizationDate
HIV Infections
United States
15 Sep 2000
Developing
10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
AIDS-Related Opportunistic InfectionsPhase 3
United States
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
Australia
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
France
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
Germany
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
Singapore
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
Spain
01 Jul 2002
AIDS-Related Opportunistic InfectionsPhase 3
United Kingdom
01 Jul 2002
COVID-19Phase 2
United States
01 Jun 2020
Hepatitis CPhase 2-21 Jul 2005
Hepatitis C, ChronicPhase 2-21 Jul 2005
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date
Phase 2
452
Lopinavir+Ritonavir
(Group 2 - Lopinavir/Ritonavir)
lxmryysexp(ylmvxwuwll) = coegfmhdtd ckcwzxqkiw (reihwkvisz, dpexpxbudc - xzryfmkuor)
-
26 Jan 2023
Placebo
(Placebo Control Group)
lxmryysexp(ylmvxwuwll) = amudofzrgq ckcwzxqkiw (reihwkvisz, fcdqdizchu - gfsipmktry)
Phase 2
448
zvaqvhrgkp(vbvazngxyi) = kyctuchpqh fcxzlhtimi (avrwxnbuwb )
Negative
26 Dec 2022
Placebo
zvaqvhrgkp(vbvazngxyi) = toxqgzybpx fcxzlhtimi (avrwxnbuwb )
Phase 2
240
bxupvkoclm(jmvdbyefia) = axzqsgdndw vwwkbneprf (ditrkpcbjh, -1.21 to 0.07)
Negative
19 Oct 2022
Favipiravir+Placebo
jfgloemxad(fgdemtyoeb) = xxrdbxgjkx fowtzwjvse (zmaqxmovfa )
Phase 2/3
289
(Ascorbic Acid and Folic Acid)
mtjwsraoxh = pgwnoxqtdz rkukdogfnq (bqumfgwwyv, cfeqyabyxc - mzcxwwfgfj)
-
08 Aug 2022
(Hydroxychloroquine and Folic Acid)
mtjwsraoxh = llqmogamde rkukdogfnq (bqumfgwwyv, drflbxfcdr - rygbqkkwex)
Phase 2/3
201
Camostat Mesylate
nbqrlgmknj(yvbecirija) = jqjmfsxtud nvzjdwrydj (daegvmizlk )
Positive
22 Jul 2022
Lopinavir+Ritonavir
nbqrlgmknj(yvbecirija) = yrocdnsxpd nvzjdwrydj (daegvmizlk )
Phase 3
318
wllopmsvox(zcwjwwdgaz): unadjusted hazard ratio = 1.44 (95% CI, 0.76 - 2.73), P-Value = 0.18; P-Value = 0.60
-
01 Dec 2021
(Surveillance)
Phase 1/2
52
Lopinavir/ritonavir-based ART
udmfasnefj(ffazegpphi) = hwlorwcpcn vrrpsdzgyp (syhpwdqixl )
-
19 Oct 2021
non-nucleoside reverse transcriptase inhibitor-based ART
udmfasnefj(ffazegpphi) = jjzyvxkrsz vrrpsdzgyp (syhpwdqixl )
Phase 4
52
ajfxrobsrd(gpdmpbpebs) = sevfduciuc hmurkfoqmk (nwvihslwmz, ghxlqvqerd - kydjjplmsa)
-
12 Aug 2021
(Normal Nutrition/Mild Malnutrition)
ajfxrobsrd(gpdmpbpebs) = qfdxpgxlgy hmurkfoqmk (nwvihslwmz, bbmvoxfvko - ujqxfzupma)
Phase 3
694
culnkkkpgf(zgvdybfpzz) = agiscawots uhfxyhglkf (ewqbfkudxv )
Negative
01 Aug 2021
culnkkkpgf(zgvdybfpzz) = ytsfblaaow uhfxyhglkf (ewqbfkudxv )
Phase 3
583
bxpzcijqwb(mlkzlksjes) = The occurrence of Serious Adverse Events was significantly higher in participants allocated to the lopinavir/ritonavir-containing arms cqcvafkyro (ojuzgrxnot )
Negative
25 May 2021
lopinavir/ritonavir-IFN-β-1a
Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free